

Conjugated linoleic acid down-regulates expression of resistin and adiponectin in fully differentiated 3T3-F442A cells

Efrat Forti · Ruth Z. Birk

Published online: 19 September 2007
© Springer-Verlag and NuGO 2007


Conjugated linoleic acid (CLA) is a naturally occurring derivative of linoleic acid found in dairy products [1]. Dietary supplementation of CLA is known to have several beneficial health effects as an anti-carcinogenic, anti-atherogenic, hypocholesterolemic, anti-diabetic and anti-obesity agent [2–5].

Adipose tissue produces a variety of factors, which contribute to insulin resistance characteristic of obesity and obesity-linked type 2 diabetes [6–7]. To explore the possible molecular link between CLA and its anti-diabetic effects, we studied the mRNA expression levels of several molecular markers of diabetes following exposure to CLA [8–11].

Fully differentiated 3T3-F442A cells were treated either by supplement with CLA or linoleic acid (LA, positive control), (100 μ M) or untreated (negative control) for 24 h. Subsequently, total RNA was extracted and transcript levels of resistin, adiponectin and PPAR γ were assayed by quantitative RT-PCR and normalized to GAPDH (house

keeping gene). Supplementation of CLA significantly down-regulated the mRNA levels of resistin and adiponectin (to 20 and 30%, respectively), as compared to LA

Fig. 1 Effect of linoleic and CLA treatment on resistin, adiponectin, and PPAR γ mRNA levels in 3T3-F442A adipocytes. Confluent 3T3-F442A cells were induced to differentiate as described in “Materials and methods”. At day 10 of differentiation the cells were treated with 100 μ M of CLA and Linoleic acid (LA) for 24 h. For each sample, transcript levels of *Resistin* (a), *Adiponectin* (b) and *PPAR γ* (c) were determined by QPCR and were normalized to internal house keeping control gene levels (*GAPDH*). The results are shown relative to control cells (untreated). Results expressed as mean + SE of three independent experiments ($n = 3$). Columns not sharing a superscript are significantly different ($P < 0.05$)



E. Forti · R. Z. Birk (✉)
National Institute for Biotechnology,
The S. Daniel Abraham International Center
for Health and Nutrition, Faculty of Health Sciences,
Ben Gurion University of the Negev, Beer-Sheva, Israel
e-mail: rbirk@bgu.ac.il

and untreated-control adipocytes (Fig. 1a, b). PPAR γ mRNA levels did not change significantly following CLA supplementation (Fig. 1c). The present results indicate that CLA supplementation down-regulates both resistin and adiponectin, adipokines known to either ameliorate or deteriorate insulin sensitivity, respectively. Further work is currently underway.

Acknowledgment This work was supported by the Danona research grant.

References

1. Boylston LH, Chang MJ, Luedecke LO, Schultz TD (1995) Survey of the CLA contents of dairy products. *J Dairy Sci* 78:2358–2365
2. Albright PY, Storkson LW, Cook ME, Pariza MW (1997) Effect of CLA on body composition in mice. *Lipids* 32:853–858
3. Whigham LD, Cook ME, Atikson RL (2000) Conjugated linoleic acid: implications for human health. *Pharmacol Res* 42:503–510
4. Delany JP, Blohm F, Truett AA, Scimeca JA, West DB (1999) CLA rapidly reduces body fat content in mice without affecting energy intake. *Am J Physiol* 276(4 pt 2):1172–1179
5. Dugan MER, Aalhus JL, Schaefer AL, Kramer JKG (1997) The effect of CLA on fat to lean repartitioning and feed conversion in pigs. *Anim Sci* 77:723–725
6. Vega GL (2004) Obesity and the metabolic syndrome. *Minerva Endocrinol* 29:47–54
7. Schinner S, Scherbaum WA, Bornsrein SR, Barthel A (2005) Molecular mechanisms of insulin resistance. *Diabet Med* 22:674–682
8. Steppan CM, Bailey ST, Brown ER, Banerjee JB, Wright CM, Patel HR, Ahina RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. *Nature* 409:307–312
9. Diez JJ, Iglesias P (2003) The role of the novel adipocyt-derived hormone adiponectin in human disease. *Eur J Endocrinol* 148:293–300
10. Kim KH, Lee K, Moon YS, Sul HS (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. *J Biol Chem* 276:11252–11256
11. Arner P (2005) Insulin resistance in type 2 diabetes—role of the adipokines. *Curr Mol Med* 5:333–339